Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level

Blood

Volumn 103, Issue 2, 2004, Pages 465-472

  Lutz, Hans U ^a   Stammler, Pia ^b   Bianchi, Valentina ^b   Trüeb, Ralph M ^b   Hunziker, Thomas ^b   Burger, Reinhard ^b   Jelezarova, Emiliana ^b   Späth, Peter J ^b  

^a ETH ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; COMPLEMENT INHIBITION; DERMATOMYOSITIS; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MYOPATHY; PRIORITY JOURNAL; SWITZERLAND;

EID: 0942276857     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1530     Document Type: Article

References (45)

1. NIH Consensus Conference. Intravenous immunoglobulin: prevention and treatment of disease. JAMA. 1990;264:3189-3193.
2. Bendtzen K, Svenson M, Hansen M. Autoantibodies to cytokines in IVIG. J Rheumatol. 1993;20:2176-2177.
3. Rhoades CJ, Williams MA, Kelsey SM, Newland AC. Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin. Blood Rev. 2000;14:14-30.
4. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. 1982;306:1254-1258.
5. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
6. Pricop L, Redecha P, Teillaud JL, et al. Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 2001;166:531-537.
7. Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology. 1998;51:S37-S45.
8. Dalakas MC. Intravenous immunoglobulln in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 1999;22:1479-1497.
9. Hughes RAC, Gabriel CM, Gregson NA, Smith KJ. Treatment of inflammatory neuropathy. Mult Scler. 1997;3:88-92.
10. Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement: kinetic analysis of the free and surface-bound forms of the enzyme. J Biol Chem. 1998;273:16828-16835,
11. Imagawa DK, Barbour SE, Morgan BP, Wright TM, Shin HS, Ramm LE. Role of complement C9 and calcium in the generation of arachidonic acid and its metabolites from rat polymorphonuclear leukocytes. Mol Immunol. 1987;24:1263-1271.
12. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood. 1991;77:376-380.
13. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729-1735.
14. n-IgG complexes. Blood. 1996;88:184-193.
15. Jelezarova E, Lutz HU. Assembly and regulation of the complement amplification loop in blood: the role of C3b-C3b-IgG complexes. Mol Immunol. 1999;36:837-842.
16. 2-IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification. Biochem J. 2000;349:217-223.
17. Gadd KJ, Reid KBM. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J. 1981;195:471-480.
18. Anton C, Alcolea MJ, Sanchez-Corral P, Marqués G, Sanchez A, Vivanco F. C3 binds covalently to the Cγ3 domain of IgG immune aggregates during complement activation by the alternative pathway. Biochem J. 1989;257:831-838.
19. Fries LF, Gaither TA, Hammer CH, Frank MM. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med. 1984;160:1640-1655.
20. Sahu A, Pangburn MK. Covalent attachment of human complement C3 to IgG: identification of the amino acid residue involved in ester linkage formation. J Biol Chem. 1994;269:28997-29002.
21. Lutz HU, Stammler P, Faster S. Preferential formation of C3b-IgG complexes in vitro and in vivo from nascent C3b and naturally occurring anti-band 3 antibodies. J Biol Chem. 1993;268:17418-17426.
22. Vidarte L, Pastor C, Mas S, et al. Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1. J Biol Chem. 2001;276:38217-38223.
23. Trüeb RM. Dermatomyositis. Dermatol Ther. 2001;14:70-80.
24. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993;100:124-127.
25. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
26. Vyse TJ, Späth PJ, Davies KA, et al. Hereditary complement factor I deficiency. Q J Med. 1994;87:385-401.
27. Tack BF, Prahl JW. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976;15:4513-4521.
28. Janatova J, Lorenz PE, Schechter AN, Prahl JW, Tack BF. Third component of human complement: appearance of sulfhydryl group following chemical or enzymatic inactivation. Biochemistry. 1980;19:4471-4478.
29. Fasler S, Skvaril F, Lutz HU. Electrophoretic properties of human IgG and its subclasses on sodium dodecyl-sulfate-polyacrylamide gel electrophoresis and immunoblots. Anal Biochem. 1988;174:593-600.
30. Lutz HU, Nater M, Stammler P. Naturally occurring anti-band 3 antibodies have a unique affinity for C3. Immunology. 1993;80:191-196.
31. 2-IgG complexes retain dimeric C3 fragments at all levels of inactivation. J Biol Chem. Prepublished on October 3, 2003, as manuscript M304613200.
32. Mollnes TE, Hogasen K, Decarolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol. 1998;48:312-317.
33. Oppermann M, Baumgarten H, Brandt E, Gottsleben W, Kurts C, Gotze O. Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays. J Immunol Methods. 1990;133:181-190.
34. Lin RY, Astiz ME, Saxon JC, Saha DC, Rackow EC, Alterations in C3, C4, factor B, and related metabolites in septic shock. Clin Immunol Immunopathol. 1993;69:136-142.
35. Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum, I: requirements for factor H vs CR1 cofactor activity. J Immunol. 1982;129:2051-2060.
36. Mollnes TE, Andreassen IH, Hogasen K, Hack CE, Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol. 1997;34:719-729.
37. Kaveri SV, Wang HT, Rowen D, Kazatchkine MD, Kohler H. Monoclonal anti-idiotypic antibodies against human anti-thyroglobulin autoantibodies recognize idiotopes shared by disease-associated and natural anti-thyroglobulin autoantibodies. Clin Immunol Immunopathol. 1993;69:333-340.
38. Kazatchkine MD, Kaveri SV. Advances in immunology: immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-755.
39. DeKeyser F, DeKeyser H, Kazatchkine MD, Rossi F, Dang H, Talal N. Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. Clin Exp Rheumatol. 1996;14:587-591.
40. Lundkvist I, van Doom PA, Vermeulen M, Brand A. Spontaneous recovery from the Guillain-Barre syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin Immunol Immunopathol. 1993;67:192-198.
41. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of anti-idiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A. 1987;84:828-831.
42. Bjorkander J, Hammarstrom L, Smith CI, Buckley RH, Cunningham-Rundles C, Hanson LA. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol. 1987;7:8-15.
43. Lutz HU, Stammler P, Jelezarova E. Natural inhibitors of complement amplification: anti-C3 antibodies from IVIG stimulate inactivation of C3bn-containing complexes. Immunopharmacology. 2000;49(suppl):67.
44. 2-mediated anti-complement activity. Clin Exp Immunol. 1997;110:122-126.
45. 2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med. 2003;9:431-438.